Company intelligence / Profile preview

CMTx Biotech

Stony Brook, New York, United Statescmtxbiotech.com ↗

Ownership: Private
Development stage: Other

Overview

Lead candidate Incyclinide (CMT-3/COL-3) has completed IND-enabling studies and has been tested safely in humans in other indications. The company received a $315,000 Clinical Trial Planning Grant from the NIH's National Center for Advancing Translational Sciences to finalize a Phase II trial of incyclinide for treatment of hospitalized COVID-19 patients.

Therapeutic areas: OtherPulmonologyRare DiseasesInfectious Diseases
Modalities: Small moleculesChemically-modified tetracyclines (CMTs)
Industry: Biotech

Drug pipeline

1 asset

CMTx R2

Unknown

Beyond the preview

Go deeper on CMTx Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMTx Biotech.

Explore the full profile